Business Wire

The LYCRA Company Launches LYCRA® FitSense™ Technology

5.9.2019 12:00:00 EEST | Business Wire | Press release

Share

The LYCRA Company, a leader in innovative fiber and technology solutions for the apparel industry, today announced the global launch of new LYCRA® FitSense™ technology. This groundbreaking innovation is a patented water-based dispersion that features the same molecule as LYCRA® fiber, but in liquid form.

LYCRA® FitSense™ technology is screen printed onto fabric containing LYCRA® fiber to deliver targeted lightweight support that can be combined with visual effects like patterns or color blocks. As a result, sewn-in panels or extra seams that may restrict movement and cause discomfort could be eliminated and the consumer’s need for great-fitting, ultra-comfortable garments is satisfied, giving support just where it is needed.

“We first offered LYCRA® FitSense™ technology to key customers in Europe and the U.S. and we’re so thrilled with the results that we’re launching it globally,” said Serge Vigouroux, executive vice president, new ventures & marketing at The LYCRA Company. “Customer feedback and product reviews have been extremely positive, and we’ve had many new inquiries from customers interested in adopting the technology.”

LYCRA® FitSense™ technology can transform activewear and athleisure apparel (leggings and tops) and intimate apparel (bras, sports bras, bralettes, underwear and shapewear) by adding lightweight power, soft shaping and lift, and targeted support without sacrificing comfort.

“This innovation is a game-changer for our apparel business that, until now, focused primarily on fiber technologies,” said Vigouroux. “We are already looking into new formulas, additional application processes, and other apparel end uses to expand this technology further.”

LYCRA® FitSense™ technology offers printers, garment makers, brands and retailers a host of benefits. This solution helps streamline garment manufacturing, offers unlimited design possibilities that provide functional benefits, and differentiates garments by providing a premium offering made with a breakthrough innovation.

To learn more about LYCRA® FitSense™ technology and the value and benefits it adds to apparel, visit connect.lycra.com. If you will be at Intertextile from September 25-27, visit ZhiNan Zhou from The LYCRA Company at Booth E56 in Hall 4.1. For show information, visit Intertextile.com.

About The LYCRA Company

The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries, as well as specialty chemicals used in the spandex and polyurethane value chains. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, L by LYCRA®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX®, TACTEL®, and TERATHANE®. While The LYCRA Company’s name is new, its legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company is focused on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.thelycracompany.com.

LYCRA ® and FitSense™ are trademarks of The LYCRA Company.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Karie Ford
+1.302.287.3095
Karie.J.Ford@lycra.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Integrated Hubs for Green Chemistry Research Aim to Transform How Chemicals and Materials Are Designed12.11.2026 18:00:00 EET | Press release

The Gordon and Betty Moore Foundation today announced four Integrated Research Hubs to explore new frontiers in chemical design, from materials that respond to their surroundings to molecules designed for safety from the start. Bringing together global researchers across institutions and disciplines, the hubs will investigate fundamental principles that could enable new capabilities in chemicals and materials while improving performance and protecting human health and the environment. The research priorities emerged through extensive engagement with the scientific community to identify the questions that could transform what chemistry can achieve. Each hub will connect researchers across institutions around one of four green chemistry focus areas: Safer molecular design: Led by The George Washington University, this hub will combine artificial intelligence and quantum chemistry to embed safety into chemical design from the outset. Adaptive catalytic systems: Led by the Max Planck Insti

Roquette Highlights Scalable Excipient and Capsule Solutions for Regional and Global Pharmaceutical Markets at CPHI India 202612.11.2026 17:00:00 EET | Press release

Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, will showcase its comprehensive portfolio of excipient and capsule solutions at CPHI India 2026, Hall 1, Booth 1I12 from November 23 to 25, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112803410/en/ Meet Roquette at CPHI India 2026, Hall 1, Booth 1I12 At the event, Roquette will demonstrate how it helps pharmaceutical manufacturers accelerate the journey from formulation to market with confidence. By combining technical expertise, trusted quality, meaningful innovation and close collaboration, Roquette helps customers address formulation, scale-up and manufacturing challenges across a broad range of pharmaceutical applications. As India continues to play a critical role in supplying medicines to patients around the world, pharmaceutical manufacturers face increasing demands for quality, regulatory compliance,

Tigo Energy and Google Cloud Pair AI-Powered Tools for Solar Installers and Utilities12.11.2026 16:00:00 EET | Press release

Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced a collaboration with Google Cloud to develop AI-enabled operational workflows for solar installers and distributed energy portfolios. By making core Tigo data and software products available through Google Cloud, Tigo aims to deliver faster deployment, simplified data integration, and additional insights with Gemini. The resulting workflows will help installers, asset managers, and energy operators more easily identify issues, prioritize actions, and automate routine operational tasks across growing fleets of distributed energy systems. As solar and storage portfolios expand, energy businesses are increasingly responsible for managing more sites, more system data, and more customer interactions without a proportional increase in operational resources. Through collaboration with Google Cloud, Tigo is developing AI-assisted workflows to help opera

Patsnap Releases State of Pharma Intelligence 2026 Report, Reveals Pharma's Cautious Embrace of AI in Decision-Making12.11.2026 16:00:00 EET | Press release

Patsnap, the AI-native innovation intelligence company for IP and R&D teams, today released "State of Pharma Intelligence 2026: The Confidence to Act", a benchmark report on how pharma teams use and trust AI in R&D, competitive intelligence and business development decisions. The report draws on responses from 130 senior leaders at Director level or above across the United States, the United Kingdom, Germany, Switzerland, and France, spanning drug developers, CDMOs/CMOs, CROs, and consulting and professional services firms. The survey was fielded in August 2026 in partnership with NewtonX. Patsnap commissioned the research to understand how AI is influencing decisions across pharma R&D and business development, what builds confidence in its output, and where intelligence workflows fall short. A central finding of the survey is that speed is limited less by finding the signal, than by trusting it. Among pharma teams using AI, internal alignment (48%) and validation time (26%) are the le

REPLY: the Board of Directors Approves the Quarterly Financial Report as of 30 September 202612.11.2026 15:41:00 EET | Press release

Today, the Board of Directors of Reply [EXM, STAR: REY] approved the results as at 30 September 2026. The Group's consolidated turnover in the first nine months of the year reached €1,987.9 million, an increase of 9.2% compared to €1,819.8 million recorded on 30 September 2025. The indicators for the period are positive. Consolidated EBITDA was €354.9 million, equal to 17.9% of the consolidated revenues. As of September 2025 EBITDA was €335.5 million. EBIT, from January to September, reached €286.7 million, equal to 14.4% of the consolidated revenues. The corresponding 2025 figure was €281.0 million. Pre-tax profit, from January to September 2026, was €291.6 million, equal to 14.7% of the revenues. As of September 2025 pre-tax profit stood at €268.1 million. For the third quarter of the year, the Group’s performance is positive, with consolidated turnover for the period of €676.0 million compared to €598.5 million of the third quarter 2025. EBITDA, from July to September 2026, was equa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye